Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours

Annals of Oncology

Volumn 19, Issue 5, 2008, Pages 903-908

  Bettini, R ^a   Boninsegna, L ^a   Mantovani, W ^b   Capelli, P ^b   Bassi, C ^a   Pederzoli, P ^a   Delle Fave, G F ^c   Panzuto, F ^c   Scarpa, A ^b   Falconi, Massimo ^a  

^a Policlinico GB Rossi   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Pancreatic endocrine tumours; Pancreatic neoplasm; Pancreatic surgery; Prognostic factors; Survival

Indexed keywords

CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; KI 67 ANTIGEN; PENTETREOTIDE; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BENIGN TUMOR; CANCER MORTALITY; CATHETER ABLATION; CHEMOEMBOLIZATION; ENDOCRINE TUMOR; FEMALE; HUMAN; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PANCREAS CARCINOMA; PANCREAS RESECTION; PANCREAS SCINTISCANNING; PANCREAS TUMOR; PANCREATICODUODENECTOMY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; TUMOR CLASSIFICATION; UNIVARIATE ANALYSIS; WEIGHT REDUCTION; WORLD HEALTH ORGANIZATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; KI-67 ANTIGEN; LIVER NEOPLASMS; MALE; MIDDLE AGED; PALLIATIVE CARE; PANCREATECTOMY; PANCREATIC NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; WEIGHT LOSS;

EID: 43049134129     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm552     Document Type: Article

References (25)

1. Heitz PU, Komminoth P, Perren A et al. WHO histological classification of tumours of the endocrine pancreas. In DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds): Pathology and Genetic of Tumours of Endocrine Organs, 1st Edition. Lyon, France: IARCPress 2004; 177-182.
2. Madeira I, Terris B, Voss M et al. Prognostic factors in patients with endocrine tumours of the duodenopancreatic area. Gut 1998; 43: 422-427.
3. Panzuto F, Nasoni S, Falconi M et al. Prognostic factors and survival in endocrine tumor patents: Comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 2005; 12: 1083-1092.
4. Phan GQ, Yeo CJ, Hruban RH et al. Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: Review of 125 patients. J Gastrointest Surg 1998; 2: 472-482.
5. Schindl M, Kaczirek K, Kaserer K, Niederle B. Is the new classificaton of neuroendocrine pancreatic tumors of clinical help? World J Surg 2000; 24: 1312-1318.
6. Rindi G, Bordi C. Endocrine tumours of the gastrointestinal tract: aetiology, molecular pathogenesis and genetics. Best Pract Res Clin Gastroenterol 2005; 19: 519-534.
7. Soreide O, Berstad T, Bakka A et al. Surgical treatment as a principle in patients with advanced abdominal carcinoid tumors. Surgery 1992; 111: 48-54.
8. Johanson V, Tisell LE, Olbe L et al. Comparison of survival between malignant neuroendocrine tumours of midgut and pancreatic origin. Br J Cancer 1999; 80: 1259-1261.
9. Corleto VD, Delle FG, Jensen RT. Molecular insights into gastrointestinal neuroendocrine tumours: Importance and recent advances. Dig Liver Dis 2002; 34: 668-680.
10. Couvelard A. [Gastro-Intestinal endocrine tumors: Morphological and clinicopathological characteristics]. Ann Pathol 2005; 25: 499-509.
11. Kent RB, 3rd, van Heerden JA, Weiland LH. Nonfunctioning islet cell tumors. Ann Surg 1981; 193: 185-190.
12. Bartsch DK, Schilling T, Ramaswamy A et al. Management of nonfunctioning islet cell carcinomas, World J Surg 2000; 24: 1418-1424.
13. Evans DB, Skibber JM, Lee JE et al. Nonfunctioning islet cell carcinoma of the pancreas. Surgery 1993; 114: 1175-1181; discussion 1181-1172.
14. Solorzano CC, Lee JE, Pisters PW et al. Nonfunctioning islet cell carcinoma of the pancreas: Survival results in a contemporary series of 163 patients. Surgery 2001; 130: 1078-1085.
15. Gullo L, Migliori M, Falconi M et al. Nonfunctioning pancreatic endocrine tumors: A multicenter clinical study. Am J Gastroenterol 2003; 96: 2435-2439.
16. Chu QD, Hill HC, Douglass HO Jr et al. Predictive factors associated with long-term survival in patients with neuroendocrine tumors of the pancreas. Ann Surg Oncol 2002; 9: 855-862.
17. Tomassetti P, Campana D, Piscitelli L et al. Endocrine pancreatic tumors: Factors correlated with survival. Ann Oncol 2005; 16: 1808-1810.
18. Solcia E, Kloppel G, Sobin L. Histological Typing of Endocrine Tumours. Berlin, Germany: Springer-Verlag 2000.
19. Falconi, M, Plockinger U, Kwekkeboom DJ et al. Well-differentiated pancreatic nonfunctioning tumors/carcinoma. Neuroendocrinology 2006; 84: 196-211.
20. Falconi M, Bassi C, Bonora A et al. Role of chemoembolization in synchronous liver metastases from pancreatic endocrine tumours. Dig Surg 1999; 16: 32-38.
21. Butturini G, Bettini R, Missiaglia E et al. Predictive factors of efficacy of the somatostatin analogue octreolide as first line theraphy for advanced pancreatic endocrine carcinoma. Endocr Relat Cancer 2006; 13: 1213-1221.
22. La Rosa S, Sessa F, Capella C et al. Prognostic criteria in nonfunctoning pancreatic endocrine tumours. Virchows Arch 1996; 429: 323-333.
23. Moertel CG, Kvols LK, O'Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991; 68: 227-232.
24. Rigaud G, Missiaglia E, Moore PS et al. High resolution allelotype of nonfunctional pancreatic endocrine tumors: Identification of two molecular subgroups with clinical implicalions, Cancer Res 2001; 61: 285-292.
25. Pelosi G, Bresaola E, Bogina G et al. Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin sections is an independent predictor for malignancy: A comparative study with proliferating-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and other clinicopathologic variables. Hum Pathol 1996; 27: 1124-1134.